Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4 Suppl 4
|
| pubmed:dateCreated |
1993-9-1
|
| pubmed:abstractText |
Allogeneic bone marrow transplantation (BMT) has been shown to result in long-term disease-free survival in patients with leukemia. However, the utility of this treatment approach is limited by treatment-related morbidity and mortality. We present an update of a study in which a BMT preparative regimen consisting of a 4-day course of busulfan and a 2-day course of cyclophosphamide (BuCy2) was used in patients with chronic myelogenous leukemia. Patient survival depended on disease stage, with a 58% survival rate for patients in first chronic phase, 41% for those in accelerated phase, and 25% for those in the blast transformation stage. There was a significant difference in patient survival between those who received transplants within 1 year of diagnosis and those who received transplants more than 1 year after diagnosis (70% v 40%). This difference appeared to be due to the extent of previous exposure to busulfan. The overall mortality rate in this study was 46%. We conclude that the BuCy2 preparative regimen is similar in effectiveness to regimens that include total body irradiation and results in comparable levels of transplant-related mortality. Our results strongly indicate that patients with chronic myelogenous leukemia who receive BMT within the first year after diagnosis have a significantly better clinical outcome than those who receive BMT later in the course of the disease.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0093-7754
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
27-31; quiz 32
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8342072-Adolescent,
pubmed-meshheading:8342072-Adult,
pubmed-meshheading:8342072-Antineoplastic Agents,
pubmed-meshheading:8342072-Bone Marrow Transplantation,
pubmed-meshheading:8342072-Busulfan,
pubmed-meshheading:8342072-Child,
pubmed-meshheading:8342072-Combined Modality Therapy,
pubmed-meshheading:8342072-Cyclophosphamide,
pubmed-meshheading:8342072-Female,
pubmed-meshheading:8342072-Humans,
pubmed-meshheading:8342072-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:8342072-Male,
pubmed-meshheading:8342072-Middle Aged,
pubmed-meshheading:8342072-Morbidity,
pubmed-meshheading:8342072-Premedication,
pubmed-meshheading:8342072-Transplantation, Homologous,
pubmed-meshheading:8342072-Treatment Outcome
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update.
|
| pubmed:affiliation |
Department of Neoplastic Diseases, Hahnemann University, Philadelphia, PA 19102.
|
| pubmed:publicationType |
Journal Article
|